Vectura : Lyon manufacturing facility returns to the Vectura Group

July 01, 2016 at 7:07 AM

Chippenham, UK - 1 July: Vectura Group plc (LSE: VEC) ('Vectura', 'the Group'), an industry-leading inhaled airways disease focused business, confirms that, as expected, the lease of its manufacturing facility and oral product business in Saint-Quentin-Fallavier, Lyon, France (together 'the Facility') to Aenova France SAS ('Aenova') expired on 30 June 2016. The Facility transferred back to the Group upon expiry.

The Facility currently manufactures seven oral products for the Group's partners. Five products use the Geomatrix family of technologies: Diclofenac-ratiopharm-uno, Coruno, ZYFLO CR, Madopar DR/Prolopaand Sular, whilst Lodotra/RAYOS uses the Geoclock chronotechnology. The Facility also manufactures one other oral product, Triglide, based on the Group's solubilisation technology. In addition, there are currently a number of pipeline projects in development, including the first complex oral generic under the Group's strategic partnership with Hikma Pharmaceuticals (SKP-1056). The Facility has cGMP status, with approvals from the European Medicines Agency, the FDA, ANVISA (Brazil) and KFDA (South Korea) amongst others.

A number of initiatives are underway to maximise the value of the Facility now that it has returned to the Group's control, leveraging proven capabilities in multilayer tableting, oral technology innovation and the high quality manufacturing capacity at the Lyon site.

David Lescuyer, Executive Vice President, Oral Business, commented:

'We are very pleased that the Lyon facility returns to the Group at this exciting time. We have a strong high quality base with the return of the Facility and we are confident of growing the business and creating future value by working with existing and new partners and leveraging our proven innovation and technology.'

- Ends -

Enquiries

About Vectura

Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading inhaled airways disease focused business with proprietary formulation and devices across DPI, pMDI and smart nebulisation platforms. With our extensive range of technologies, capabilities and collaborations, we believe we can become a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases. In June 2016 Vectura completed a merger with Skyepharma PLC.

Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which havelicence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Chiesi, Almirall, Janssen, and Tianjin KingYork.

For further information, please visit Vectura's website at www.vectura.com.

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Tags: